Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| No statute on record | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.7% | +53.3% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.4% |
| LOCKARD, JON MCCLELLAND | 1 | 74.5% | +27.0% |
| BENAVIDES, JENNIFER ANN | 1 | 50.0% | +44.9% |
| GIBBS, TERRA C | 1 | 64.1% | +10.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16649572 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | GIBBS, TERRA C | 15d |
| 19097573 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING | PUTTLITZ, KARL J | 16d |
| 19097593 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING | LOCKARD, JON MCCLELLAND | 33d |
| 18637337 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | BENAVIDES, JENNIFER ANN | 35d |
| 19329403 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | HUYNH, PHUONG N | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1646 | 1 |
| 1647 | 1 |
| 1675 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19329403 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | HUYNH, PHUONG N | 1641 | DPOther | Non-Final OA | — | Pending | Sep 15, 2025 |
| 19097573 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING | PUTTLITZ, KARL J | 1646 | Other | Final Rejection | 16d | Pending | Apr 01, 2025 |
| 19097593 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING | LOCKARD, JON MCCLELLAND | 1647 | §112 | Final Rejection | 33d | Pending | Apr 01, 2025 |
| 18637337 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | BENAVIDES, JENNIFER ANN | 1675 | Other | Final Rejection | 35d | Pending | Apr 16, 2024 |
| 16649572 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | GIBBS, TERRA C | 1635 | §103 | Final Rejection | 15d | Pending | Mar 20, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial